Find out the facts about vibegron
Use the keyword search below to request summary discussions of vibegron clinical trial results and use-related topics. Separate each keyword with a comma.
Search results (1 result)
-
Phase 3 EMPOWUR Trial
View Response Letter -
Long-Term Safety and Efficacy in the Phase 3 EMPOWUR Extension Trial
View Response Letter -
GEMTESA® (vibegron) Mechanism of Action
View Response Letter -
GEMTESA® (vibegron) Phase 3 EMPOWUR Trial Inclusion and Exclusion Criteria
View Response Letter -
GEMTESA® (vibegron) Blood Pressure
View Response Letter -
Vibegron in Patients Aged ≥65 Years
View Response Letter -
GEMTESA® Digoxin
View Response Letter -
GEMTESA® Phase 3 EMPOWUR Trial Concomitant Medications
View Response Letter -
GEMTESA® Phase 3 EMPOWUR Trial - Prior OAB Pharmacotherapy
View Response Letter -
GEMTESA® Tablet and Light Green Film Coating Ingredients
View Response Letter -
GEMTESA® Crushed Tablets
View Response Letter -
GEMTESA® Temperature Excursions
View Response Letter -
Vibegron: Health-Related Quality of Life
View Response Letter -
GEMTESA® EMPOWUR Patient Global Impression of Improvement (PGI) Results
View Response Letter
Try adjusting your keyword(s). Separate each keyword with a comma. You can also submit a question, or contact Urovant Medical Affairs at 833-UROVANT.
Documents obtained from search may contain information that is not included in the approved product labeling. Urovant does not endorse the use of its products in a manner not consistent with the approved label. Please refer to the full product labeling for complete prescribing information and important safety information.
Did the search result(s) address your interest? If not, try adjusting your keyword(s). You can also submit a question, or contact Urovant Medical Affairs at 833-UROVANT.
Documents obtained from search may contain information that is not included in the approved product labeling. Urovant does not endorse the use of its products in a manner not consistent with the approved label. Please refer to the full product labeling for complete prescribing information and important safety information.
Success!
The requested response letter will be delivered to the email address you provided.
Documents obtained from search may contain information that is not included in the approved product labeling. Urovant does not endorse the use of its products in a manner not consistent with the approved label. Please refer to the full product labeling for complete prescribing information and important safety information.
Related Information
Report Adverse Events
833-UROVANT (Option 1)
Report Product Complaints
833-UROVANT (Option 1)